General News Regulated Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema EN May 25, 2023
General News Oxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLC EN May 22, 2023
News Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC EN NL May 19, 2023
General News Regulated Oxurion Announces Results of the Annual Shareholders’ Meeting of 2 May 2023 EN May 15, 2023
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL May 12, 2023
News Regulated Transparency/Denominator Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC EN NL May 12, 2023
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL May 5, 2023
News Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC EN NL May 3, 2023
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL April 28, 2023
General News Oxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLC EN April 27, 2023
News Regulated Transparency/Denominator Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC EN NL April 24, 2023
News Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC EN NL April 14, 2023
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL April 7, 2023
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL March 31, 2023
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL March 24, 2023
General News Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas Special Opportunities LL EN March 20, 2023
General News Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes EN March 14, 2023
News Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Negma Group EN NL March 9, 2023
